Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience

Nivolumab and ipilimumab combination became the first-line standard in advanced melanoma. We assessed its efficacy in a real-life study in Poland. In a one-year follow-up, we evaluated the medical records of 50 melanoma patients treated with that modality in five oncology centers. We recorded therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacholczak-Madej, Renata, Grela-Wojewoda, Aleksandra, Puskulluoglu, Mirosława, Lompart, Joanna, Las-Jankowska, Manuela, Krawczak, Katarzyna, Wrona, Ewa, Zaręba, Lech, Żubrowska, Justyna, Walocha, Jerzy, Bazan-Socha, Stanisława, Ziobro, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598919/
https://www.ncbi.nlm.nih.gov/pubmed/36289790
http://dx.doi.org/10.3390/biomedicines10102528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598919/
https://www.ncbi.nlm.nih.gov/pubmed/36289790
http://dx.doi.org/10.3390/biomedicines10102528

Ejemplares similares